A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), Chronic Inducible Urticaria (“CIndU”) and Asthma. We are evaluating additional indications in mast cell driven diseases for potential future development and we have also historically supported development programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as and stem cell transplant conditioning regimens. Our lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (“SCF”) from binding to and signaling through the CD117 (“c-Kit”) receptor on mast and stem cells.
| Metric | TTM | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | 0 | - | - | - |
| Net Income | -91M | -64M | -38M | -31M |
| EPS | $-5.82 | $-4.28 | $-2.50 | $-26.90 |
| Free Cash Flow | 0 | -52M | -46M | -34M |
| ROIC | -128.3% | -82.2% | -112.4% | -44.1% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | 0.21 | 0.34 | 0.35 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -93M | -69M | -51M | -37M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -786.6% | -112.7% | -104.7% | -178.2% |
| Shares Outstanding | 28M | 15M | 15M | 1M |
| Metric | 2021 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -37M | -51M | -69M | -93M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -31M | -38M | -64M | -91M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -44.1% | -112.4% | -82.2% | -128.3% |
| ROE | -178.2% | -104.7% | -112.7% | -786.6% |
| ROA | -52.4% | -77.9% | -90.0% | -158.4% |
| Cash Flow | ||||
| Op. Cash Flow | -34M | -46M | -52M | -76M |
| Free Cash Flow | -34M | -46M | -52M | 0 |
| Owner Earnings | -35M | -51M | -58M | -83M |
| CapEx | 0 | 0 | 0 | 0 |
| Maint. CapEx | 377K | 975K | 1.1M | 1.1M |
| Growth CapEx | N/A | N/A | N/A | 0 |
| D&A | 377K | 975K | 1.1M | 1.1M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.0M | 4.1M | 5.2M | 5.2M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | N/A | N/A | N/A | -51M |
| Cash & Equiv. | N/A | N/A | N/A | 51M |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.35 | 0.34 | 0.21 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A |
| Equity | 70M | 36M | 78M | 12M |
| Total Assets | 94M | 48M | 95M | 57M |
| Total Liabilities | 24M | 12M | 16M | 46M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -67M | -105M | -170M | -170M |
| Working Capital | 80M | 35M | 77M | 77M |
| Current Assets | 88M | 42M | 89M | 89M |
| Current Liabilities | 8.0M | 7.1M | 12M | 12M |
| Per Share Data | ||||
| EPS | -26.90 | -2.50 | -4.28 | -5.82 |
| Owner EPS | -30.82 | -3.38 | -3.88 | -2.96 |
| Book Value | 61.04 | 2.39 | 5.21 | 0.41 |
| Cash Flow/Share | -29.57 | -3.04 | -3.46 | -3.21 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.1M | 15.1M | 15.1M | 28.0M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -0.2 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | 1.5 | 2.5 | 1.4 | 2.2 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | -33.2% | -51.6% | -48.1% | N/A |
| Market Cap | 101M | 89M | 108M | 26M |
| Avg. Price | 99.27 | 25.62 | 12.96 | 0.92 |
| Year-End Price | 89.00 | 5.90 | 7.18 | 0.92 |
Jasper Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Jasper Therapeutics, Inc. (JSPR) has a 5-year average return on invested capital (ROIC) of -79.5%. This is below average and may indicate limited pricing power.
Jasper Therapeutics, Inc. (JSPR) has a market capitalization of $26M. It is classified as a small-cap stock.
Jasper Therapeutics, Inc. (JSPR) does not currently pay a regular dividend.
Jasper Therapeutics, Inc. (JSPR) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Jasper Therapeutics, Inc. (JSPR) generated $-52 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Jasper Therapeutics, Inc. (JSPR) has a debt-to-equity ratio of 0.21. This indicates a conservatively financed balance sheet.
Jasper Therapeutics, Inc. (JSPR) reported earnings per share (EPS) of $-4.28 in its most recent fiscal year.
Jasper Therapeutics, Inc. (JSPR) has a return on equity (ROE) of -112.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Jasper Therapeutics, Inc. (JSPR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Jasper Therapeutics, Inc. (JSPR) has a book value per share of $5.21, based on its most recent annual SEC filing.